 | Up a level |
Journal Article
Javle, Milind, Roychowdhury, Sameek, Kelley, Robin Kate, Sadeghi, Saeed, Macarulla, Teresa 
ORCID: 0000-0002-5856-4082, Weiss, Karl Heinz, Waldschmidt, Dirk-Thomas, Goyal, Lipika, Borbath, Ivan, El-Khoueiry, Anthony, Borad, Mitesh J., Yong, Wei Peng, Philip, Philip A., Bitzer, Michael, Tanasanvimon, Surbpong, Li, Ai, Pande, Amit, Soifer, Harris S., Shepherd, Stacie Peacock, Moran, Susan, Zhu, Andrew X., Bekaii-Saab, Tanios S. and Abou-Alfa, Ghassan K.
(2021).
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Lancet Gastroenterol. Hepatol., 6 (10).
S. 803 - 816.
SAN DIEGO:
ELSEVIER INC.
ISSN 2468-1253
Javle, Milind M., Roychowdhury, Sameek, Kelley, Robin Kate, Sadeghi, Saeed, Macarulla, Teresa, Waldschmidt, Dirk Thomas, Goyal, Lipika, Borbath, Ivan, El-Khoueiry, Anthony B., Yong, Wei-Peng, Philip, Philip Agop, Bitzer, Michael, Tanasanvimon, Suebpong, Pande, Amit, Shepherd, Stacie Peacock, Moran, Susan and Abou-Alfa, Ghassan K. (2021). Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. J. Clin. Oncol., 39 (3). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755